Previous 10 | Next 10 |
2023-08-07 05:24:35 ET Summary Generation Bio is a global leader in non-viral DNA therapeutics, aiming to deliver lifelong genetic medicines on a disruptive scale. The company has three core technologies, including a high-capacity ceDNA construct and a ctLNP delivery system. G...
2023-08-03 10:13:18 ET Generation Bio press release ( NASDAQ: GBIO ): Q2 GAAP EPS of -$0.47 beats by $0.07 . Revenue of $880M. Cash, cash equivalents, and marketable securities were $314.1 million as of June 30, 2023, compared to $279.1 million as of...
CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Matt Norkunas, M.D., chief financial officer, will present at the 2023 Canaccord He...
CAMBRIDGE, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co . (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and second quarter 2023 financial results. “We continu...
2023-07-14 08:15:40 ET First Wave BioPharma ( FWBI ) -32% . Healthcare Triangle ( HCTI ) -31% . SunCar Technology Group ( SDA ) -30% . Rockwell Medical ( RMTI ) -30% . Cadrenal Therapeutics ( CVKD ) -30% . Viasat ( VSAT ) -...
2023-06-23 17:09:25 ET Gainers: Morningstar ( MORN ) +8% . Annexon ( ANNX ) +5% . Cardlytics ( CDLX ) +4% . MeiraGTx Holdings ( MGTX ) +4% . Lexicon Pharmaceuticals ( LXRX ) +3% . Losers: Lulu's Fashion Lounge ( L...
CAMBRIDGE, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will present at the 20...
2023-05-10 17:28:46 ET Generation Bio press release ( NASDAQ: GBIO ): Q1 GAAP EPS of -$0.53 misses by $0.07 . Cash, cash equivalents, and marketable securities were $288.6 million as of March 31, 2023, not including an additional $47.5 million received i...
CAMBRIDGE, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in ...
2023-03-31 13:02:23 ET Summary Last week, Generation Bio announced a strategic collaboration with Moderna worth $5m upfront plus a $40m equity investment. Generation has been working on Lipid Nanoparticle Delivery Technology for gene therapies. The company has made little prog...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a ...
- Oral presentation at ASGCT described selective, high levels of therapeutic transgene delivery to T cells in vivo by cell-targeted lipid nanoparticle (ctLNP) - ASGCT poster presentations described immune-quiet DNA (iqDNA) as partially single-stranded, produced by flexible, scalab...
Data presented show immune-quiet DNA (iqDNA) is a partially single-stranded DNA cargo that maintains expression while evading innate immune sensors Rapid enzymatic synthesis continues to improve iqDNA performance through process development and the identification of novel structural ele...